Singapore

THE exuberant market response to the listing of US-based startup Livongo Health could provide a shot in the arm for Asian startups similarly focused on behavioural and preventive medicine, reckon investors who spoke to The Business Times.

Livongo, which debuted on the Nasdaq on Thursday, saw its share price surge 36 per cent to US$38.10 on the first day of trading, giving it a market cap of US$3.46 billion. This is more than four times its US$800 million valuation as at April.